Effective Management of Prostate Cancer Conclusion

Video

For High-Definition, Click

In this segment, Raoul Concepcion, MD, wraps up the discussion by noting that conversations often provide urologists with the opportunity to stay involved and provide new points of view to their peers. In closing, Daniel R. Saltzstein, MD, Bryan Mehlhaff, MD, and Steve Dobbs, FACHE, each provide their opinions on key areas of interest in prostate cancer.

Saltzstein notes that a few different areas of prostate cancer are in need of further development, such as biopsying, surveillance, radiation, surgery, and androgen deprivation therapy. With all the recent advances and new treatments approved, it's an exciting time in prostate cancer, Mehlhaff points out. However, he adds, finding a cure for the disease should remain a goal of research. In terms of reimbursement and purchasing costs, Dobbs stresses that communication and trust between physicians is an important factor.

Related Videos
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Samer A. Srour, MB ChB, MS
Carmen Guerra, MD, MSCE, FACP
Kara N. Maxwell, MD, PhD
Josep Maria Piulats Rodriguez, MD, PhD
Samer A. Srour, MB ChB, MS
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Phillip J. Koo, MD
A panel of 5 experts on renal cell carcinoma